HLA-DRB3/4/5-based susceptibility profiles in nivolumab-induced type 1 diabetes and interstitial lung disease.

Front Immunol · 2026 · PMC13269219 · PMID 42311662

Europe PMC DOI

hedged sentence

0.0503

closest p · 1.0× alpha

0.0503

boldest claim

The sentences

showed a trendp = 0.0503so close (0.05 < p ≤ 0.1)

Notably, DRB1*04:10:03 showed a trend toward increased frequency in the ICI-ILD group (p = 0.0503).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.